Floatz logo

an0025

Lung Cancer

Rutgers, The State University of New JerseyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

an0025 is also rated in:

Locally Advanced Solid TumorDormant
CC
Indicative ·
44 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
cervical cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →